Observational studyThe oncologist2025
The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors.
Observational study in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Troponin for surveillance of immune checkpoint inhibitor-associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- Role of Troponins in CardioOncology.Current treatment options in oncology · 2026Review
- Relationship between cardiac troponin and myocardial infarction: a bibliometric analysis.Journal of cardiothoracic surgery · 2026Article
- Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitor-associated arrhythmias: clinical challenges, artificial intelligence-enhanced monitoring, and management strategies.Frontiers in cardiovascular medicine · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) may lead to immune-related adverse events, including potentially life-threatening cardiovascular (CV) complications. Despite guideline-recommended troponin monitoring, limited data exist on evaluating its predictive significance.
objectiveWe aimed to assess the predictive value of serial high-sensitivity troponin I (hs-TnI) monitoring in patients treated with ICIs.
methodsA retrospective, single-center, observational study including patients treated with ICIs and performing serial hs-TnI measurements. The primary endpoint was all-cause mortality, and the secondary endpoint was CV events, defined as the composite of myocarditis, pericarditis, acute coronary syndrome, heart failure, or arrhythmias. A tree classifier model identified the most predictive hs-TnI concentration for the main study endpoints.
resultsOverall, 455 patients performed baseline (T1) and follow-up hs-TnI (T2) assessments and were included in the cohort. During a mean follow-up of 25 months (IQR [12-36]), 253 (56%) patients died, and 70 (15%) developed CV events. T2 > 8 ng/L was significantly associated with increased all-cause mortality (64% vs 48%, P < .001) and CV events (22% vs 9%, P < .001), notably HF (12% vs 4%, P = .003) and myocarditis (3% vs 0%, P = .038). A multivariable analysis confirmed that T2 > 8 ng/L was an independent predictor for all-cause mortality (HR 1.67, 95% CI: 1.29-2.17, P < .001) and CV events (HR 2.59, 95% CI: 1.50-4.46, P = .001).
conclusionsOur study emphasizes the significant role of serial troponin monitoring during ICIs therapy as an independent predictor of all-cause mortality and CV events, and suggests an optimal lower hs-TnI cutoff of >8 ng/L for risk stratification. Large prospective trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.